MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Spinocerebellar Ataxia Type 17 First Reported Case in Northern Mexico

    S. Murillo Quintana, D. Sánchez Galván, J. Mejía Chávez, S. Flores Casas, L. Hernández Salomón (Torreón, Coahuila, Mexico)

    Objective: To report the first documented case of spinocerebellar ataxia type 17 (SCA17) in northern Mexico. Background: SCA17 is an autosomal dominant neurodegenerative disorder caused…
  • 2025 International Congress

    Waveform based analysis of cervical dystonia with tremor and essential tremor using a marker-less tracking algorithm with 2D-video: evaluation of sinusoidality and rhythmicity

    JH. Shin, SM. Lee, KA. Woo, H. Jinnah, M. Hallett, V. Fung, S. Pandey, R. Helmich, M. Vidailhet, A. Shaikh, A. Fasano, HJ. Kim, B. Jeon (Seoul, Republic of Korea)

    Objective: This study aims to introduce a novel video-based waveform analysis to objectively measure two fundamental tremor characteristics—rhythmicity and sinusoidality. Background: Tremor is defined as…
  • 2025 International Congress

    A Double-Blind, Cross-Over Pilot Study Comparing Adaptive Deep Brain Stimulation (aDBS) to Conventional DBS in Parkinson’s Disease

    T. Hashimoto, J. Tanimura, T. Yako (Matsumoto, Japan)

    Objective: To compare the efficacy of adaptive deep brain stimulation (aDBS) to conventional DBS (cDBS) in Parkinson’s disease through a double-blind, cross-over pilot study. Background:…
  • 2025 International Congress

    Effect of CUE1+ Device on Motor and Non-Motor Symptoms in Parkinson’s: A Pilot Randomised Controlled Trial.

    V. Azoidou, K. Rowsell, E. Camboe, K. Dey, A. Zirra, C. Quah, T. Boyle, C. Budu, D. Gallagher, A. Noyce, C. Simonet (London, United Kingdom)

    Objective: To assess the effect CUE1+ device on motor and non-motor symptoms in people with Parkinson’s (PwP). Background: Current treatments for PwP often fail to…
  • 2025 International Congress

    A Scoping Review of Psychological Interventions across domains to improve Quality of Life in Persons with Parkinson’s Disease

    S. Desai, D. Desai (Anand, India)

    Objective: This scoping review examines the evidence for psychological interventions across the domains of therapy, activity, tele-health and integrated care for improving Quality of Life…
  • 2025 International Congress

    Transformation of Parkinson’s care through Self-Management, Remote monitoring and Timely review (SMaRT-PD): Care Pathway Mapping with Clinical Experts

    N. Howe, P. Walker, C. Mutepfa, S. Pretorius, A. Ponzo, C. Carroll, J. Suklan (Plymouth, United Kingdom)

    Objective: To elicit healthcare professionals’ perspectives on the introduction of a clinical decision support system (CDSS) to facilitate Parkinson’s disease care provision: impact on current…
  • 2025 International Congress

    Patient Perspectives on the Therapeutic Effects of Botulinum Toxin in Cervical Dystonia

    M. Relja, D. Dressler, F. Morgante, V. Trjulja (Zagreb, Croatia)

    Objective: To investigate patient perspectives on the therapeutic effects of botulinum toxin type-A  (BoNT-A) in cervical dystonia (CD) using patient s on-line survey. Background: CD…
  • 2025 International Congress

    Spinocerebellar Ataxia Type 40 (SCA-40) with a Novel Mutation in an Indian Female: A Case Report

    A. Mehta, P. Hiremath, M. Javali, P. R, L. Priya, P. Acharya (Bengaluru, India)

    Objective: To report the first Indian patient with SCA 40 who presented in the fifth decade with a novel missense mutation (c.1291C>T, p.His431Tyr), expanding the…
  • 2025 International Congress

    Anti-Yo Syndrome Presenting as an Isolated Head Tremor with Vertigo

    P. Atit, V. Mazo, R. Hurst, A. Rivera Cruz (Tampa, USA)

    Objective: To highlight the prodromal and syndromic features of Anti-Yo/PCA-1 syndrome. Background: A 50-year-old female initially presented with a 1-month history of headaches and vertigo.…
  • 2025 International Congress

    Antisense Oligonucleotide Treatment in Ataxia-Telangiectasia

    C. de Gusmao, C. Achkar, B. Ahtam, C. Berde, L. Bush, D. Chin, B. Darras, K. Faour, D. Friedmann, B. Gagoski, B. Goodlett, E. Grant, A. Gupta, S. Hills, A. Hu, J. Kim, A. Kuniholm, C. Lentucci, J. Lopes, E. Lopez, A. Luddy, B. Margus, M. Meserve, V. Natale, T. Nakayama, A. O’Connor, C. Rabideau, O. Riccardi, R. Schule, E. Sherril, L. Solo, A. Soucy, V. Suslovitch, M. Synofzik, J. Thornton, T. Yu (Boston, USA)

    Objective: Describe results of an antisense oligonucleotide (ASO) treatment trial in a patient with ataxia-telangiectasia (AT). Background: AT is a neurodegenerative, incurable disease of children…
  • « Previous Page
  • 1
  • …
  • 265
  • 266
  • 267
  • 268
  • 269
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley